4D-CT Attenuation Correction in Respiratory-Gated PET for Hypoxia Imaging: Is It Really Beneficial?
4D-PET
hypoxia
phantom
quality assurance
respiratory gating
Journal
Tomography (Ann Arbor, Mich.)
ISSN: 2379-139X
Titre abrégé: Tomography
Pays: Switzerland
ID NLM: 101671170
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
25
6
2021
Statut:
ppublish
Résumé
Previous literature has shown that 4D respiratory-gated positron emission tomography (PET) is beneficial for quantitative analysis and defining targets for boosting therapy. However the case for addition of a phase-matched 4D-computed tomography (CT) for attenuation correction (AC) is less clear. We seek to validate the use of 4D-CT for AC and investigate the impact of motion correction for low signal-to-background PET imaging of hypoxia using radiotracers such as FAZA and FMISO. A new insert for the Modus Medicals' QUASAR™ Programmable Respiratory Motion Phantom was developed in which a 3D-printed sphere was placed within the "lung" compartment while an additional compartment is added to simulate muscle/blood compartment required for hypoxia quantification. Experiments are performed at 4:1 or 2:1 signal-to-background ratio consistent with clinical FAZA and FMISO imaging. Motion blur was significant in terms of SUV
Identifiants
pubmed: 32548302
doi: 10.18383/j.tom.2019.00027
pii: TOMO.2019.00027
pmc: PMC7289254
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-249Informations de copyright
© 2020 The Authors. Published by Grapho Publications, LLC.
Déclaration de conflit d'intérêts
Conflict of Interest: None reported. Disclosures: No disclosures to report.
Références
J Appl Clin Med Phys. 2011 Nov 15;12(4):3502
pubmed: 22089005
J Nucl Med Technol. 2011 Jun;39(2):91-9
pubmed: 21565957
Nucl Med Commun. 2014 Feb;35(2):113-22
pubmed: 24352107
Transl Oncol. 2009 Dec;2(4):195-7
pubmed: 19956378
Med Phys. 2008 Sep;35(9):3998-4011
pubmed: 18841851
Med Phys. 2011 Oct;38(10):5732-7
pubmed: 21992387
Radiat Oncol. 2014 Dec 16;9:291
pubmed: 25511904
Eur Radiol. 2014 Dec;24(12):3242-50
pubmed: 25097133
Lung Cancer. 2016 Jun;96:78-86
pubmed: 27133755
Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):702-10
pubmed: 24177810
Phys Med Biol. 2016 Apr 21;61(8):3148-63
pubmed: 27007013
Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):749-54
pubmed: 23601897
J Med Imaging Radiat Oncol. 2018 Feb;62(1):81-90
pubmed: 29193781
Transl Lung Cancer Res. 2017 Dec;6(6):670-688
pubmed: 29218270
Med Phys. 2017 Dec;44(12):e430-e445
pubmed: 28905393
Acta Oncol. 2017 Sep;56(9):1181-1188
pubmed: 28537761
Eur J Nucl Med Mol Imaging. 2011 May;38(5):843-55
pubmed: 21222120
Med Phys. 2015 Jan;42(1):110-20
pubmed: 25563252
Radiother Oncol. 2012 Oct;105(1):14-20
pubmed: 23083497
Biomed Res Int. 2014;2014:167491
pubmed: 25250313
Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1381-90
pubmed: 22588628
Med Phys. 2002 Mar;29(3):366-71
pubmed: 11929020
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Br J Radiol. 2018 Jun;91(1086):20170640
pubmed: 29338327
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):618-25
pubmed: 19147026
J Nucl Med Technol. 2007 Dec;35(4):246-51
pubmed: 18006594
J Med Imaging Radiat Oncol. 2014;58(3):277-82
pubmed: 24438486
J Nucl Med. 2015 Aug;56(8):1223-8
pubmed: 26112020
Semin Nucl Med. 2012 Sep;42(5):289-307
pubmed: 22840595
J Nucl Med Technol. 2015 Sep;43(3):222-6
pubmed: 26271802
Med Phys. 2010 Sep;37(9):5037-43
pubmed: 20964223
Nucl Med Commun. 2016 Feb;37(2):162-70
pubmed: 26513056
EJNMMI Phys. 2015 Dec;2(1):4
pubmed: 26501806